PB0192 - Bleeding Rates in Severe Non-inhibitor Haemophilia A Patients Across US, EU4&UK and Japan

Background: Bleeding events can impact the health status of patients living with haemophilia.

Aims: This study aims to investigate bleeding occurrences among severe Haemophilia A patients without inhibitors in US, EU&UK (Germany, UK, France, Italy, Spain) and Japan.

Methods: The Ipsos Hemophilia Therapy Monitor is a multi-country, multi-center online medical chart review study of patients with hemophilia A and B (HA & HB). Recruited from a large access panel, 295 treating physicians in US (n=70), EU&UK (n=180; ~equal split across countries) and Japan (n=45) were screened for duration of practice in their speciality and caseload, and provided data on 1958 HA pts (EU&UK=984, US=355, JP=85), of which 1424 were non-inhibitor (NI) and had severe HA. Data collection between June to August 2021.

Results: In EU&UK, 59% of the 984 reported severe NI HA patients experienced a bleed in the last 12 months, significantly higher than 48% of reported US sample (n=171 of 355) and 40% of reported Japan sample (n=34 of 85) (p < 0.01).
Of the reported severe NI HA pts experiencing a bleed in the last 12 months (EU&UK =579, US=171, JP=34), patients in EU&UK and US were younger than in Japan (mean age of 27, 26 and 40, respectively). In Japan, 41% (n=14) of reported patients are less than 41 years compared to 85% (n=491) in EU&UK and 82% (n=140) in US. The percentage of reported patients that switched treatment since diagnosis is similar in EU&UK and Japan (68.4%, n=394 and 67.7%, n=23, respectively). In EU&UK, it is significantly higher compared to the US (53%, n=91) (p < 0.01).

Conclusion(s): Results highlight presence of regional variation across age and switch rates for severe NI HA patients who experienced bleeding in the last 12 months. These variations can be considered when reviewing or developing regionally specific clinical guidelines. Further investigation using comparator cohort is warranted.